Skip to main content

Table 1 Tumor and demographic characteristics of 253 patients with breast carcinoma and diabetes (128 on and 125 not on metformin) and 320 patients with breast carcinoma without diabetes

From: Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients – a retrospective study of clinical and tumor characteristics

Factor

Sub-group

Patients with breast carcinoma and diabetes without metformin

Patients with breast carcinoma and diabetes on metformin

Patients with breast carcinoma without diabetes

P1

P2

Median age (years)

 

69

65

60

0.034

0.0001

Median BMI (kg/m 2 )

 

29.35

30.30

25.80

0.18

0.0001

Median ASA score

 

2

2

2

0.78

0.0001

Median tumor size (cm)

 

2.1

2.05

1.8

0.46

0.014

Median number of metastatic lymph nodes

 

0.5

1

0

0.79

0.78

Age (years)

70 or less

72

96

248

0.003

0.0001

71 or more

53

32

72

BMI (kg/m 2 )

Less than 30

70

58

258

0.122

0.0001

(N = 562)

30 or more

51

63

62

  

ASA score (N = 480)

1

3

0

103

0.21

0.0001

2

77

80

119

3

38

38

22

Diet only (N = 253)

No

105

128

-

-

-

Yes

20

0

-

Therapy with sulphonylurea

No

78

69

320

-

-

Yes

47

59

0

pT tumour stage

pT1

57

63

192

0.031

0.0001

pT2

35

45

87

pT3

6

9

20

pT4

27

11

21

T3 or T4 stage

pT1 or pT2

93

108

279

0.035

0.003

pT3 or pT4

33

20

41

N stage (N = 572)

pN0

63

65

173

0.90

0.78

pN1 or pN2

62

63

146

Number of metastatic lymph nodes (N = 572)

0

63

63

173

0.68

0.75

1–3

32

39

80

4 or more

30

26

66

M stage

M0

120

124

313

0.75

0.55

M1

5

4

7

Type of invasive carcinoma

Ductal

103

115

274

0.086

0.23

Lobular or other

22

13

46

Molecular subtype of carcinoma (N = 569)

Luminal A

104

99

226

0.60

0.01

Luminal B

11

16

35

HER-2

2

1

25

Triple negative

8

11

31

Tumor differentiation (N = 566)

Well or moderate

69

73

177

0.67

0.89

Poor

56

75

136

ER status (10% or more) (N = 570)

Positive

113

115

258

0.97

0.008

Negative

12

12

60

PR status (10% or more)

Positive

96

90

207

0.28

0.049

Negative

29

37

111

ER status (1% or more) (N = 570)

Positive

114

116

263

0.87

0.011

Negative

11

12

57

PR status (1% or more)

Positive

106

99

218

0.13

0.001

Negative

19

29

102

HER-2 (N = 569)

Negative

112

110

257

0.46

0.06

Positive

13

17

60

Triple-negative tumor (N = 569)

No

117

116

286

0.49

0.53

Yes

8

11

31

  1. P1: p-value (DM not on metformin vs. DM on metformin).
  2. P2: p-value (DM not on metformin vs. DM on metformin vs. controls).
  3. ER: estrogen receptor status.
  4. PR: progesteron receptor.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us